Astute Medical, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 463 | 55.0% |
| Royalty or License | $546,317 | 21 | 17.1% |
| Consulting Fee | $320,183 | 70 | 10.0% |
| Honoraria | $195,337 | 151 | 6.1% |
| Gift | $183,770 | 127 | 5.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,551 | 40 | 2.5% |
| Food and Beverage | $44,223 | 909 | 1.4% |
| Travel and Lodging | $41,027 | 85 | 1.3% |
| Education | $20,793 | 285 | 0.7% |
| Entertainment | $2,474 | 40 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AST-132 Diamond | $705,215 | 0 | 212 |
| AST-017 Healthy Adult | $345,172 | 0 | 109 |
| Alternate Decisions for Dialysis for AKI (ADD-AKI) | $317,399 | 0 | 7 |
| AST-134 Turquoise | $112,939 | 0 | 30 |
| AST-134 TURQUOISE | $91,587 | 0 | 9 |
| Markers of Acute Pediatric Appendicitis | $53,283 | 0 | 29 |
| AST 132 Diamond | $27,778 | 0 | 19 |
| Function test using neutralized antibody against TIMP2 and IGFBP7 in CLP mice | $24,759 | 0 | 3 |
| Utility of NEPHROCHECK Test System as an early marker of AKI in patients with head and neck cancer undergoing cisplatin-based chemotherapy | $13,559 | 0 | 4 |
| Nephroclear - Diamond | $13,000 | 0 | 1 |
| ADD-AKI | $10,000 | 0 | 1 |
| Study to Identify and Validate Novel Biomarkers from Vascular Surgery Patients at Risk for Acute Kidney Injury | $5,400 | 0 | 3 |
| Study to Identify and Validate Novel Biomarkers from Acutely Ill Patients at Risk for Acute Kidney Injury | $5,400 | 0 | 3 |
| AMI003-08 VAS/AST-105 | $5,400 | 0 | 3 |
| Study to Identify and Validate Novel Biomarkers from Heart Surgery Patients at Risk for Acute Kidney Injury | $3,600 | 0 | 2 |
| Evaluation of Novel Biomarkers from Acutely Ill Patients at Risk for Acute Kidney Injury | $3,600 | 0 | 2 |
| Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury | $3,600 | 0 | 2 |
| AMI005-10 AKI/AST-111 | $3,600 | 0 | 2 |
| AMI001-08 AKI/AST-106 | $3,600 | 0 | 2 |
| Identification and Validation of Biomarkers of Acute Kidney Injury Recovery | $3,242 | 0 | 5 |
| A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury | $500.00 | 0 | 1 |
| Kinetics of cell-cycle arrest biomarkers after contrast exposure in patients at high risk for contrast induced nephropathy | $355.43 | 0 | 11 |
| Free hemoglobin in extracorporeal therapy decreases nitric oxide bioavailability and leads to oxidative stress and decreased end organ perfusion | $208.40 | 0 | 1 |
| PICS | $137.60 | 0 | 1 |
| Navigate AKI | $137.20 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Neelima Dachuri, Md, MD | Hospitalist | Augusta, GA | $201.36 | $0 |
| Paayal Mehta, Md, MD | Internal Medicine | Lawrenceville, GA | $201.35 | $0 |
| Margaret Fairhurst, D.o, D.O | Critical Care Medicine | Medford, OR | $200.60 | $0 |
| Dr. Hoang Le, M.d, M.D | Pulmonary Disease | Fountain Valley, CA | $198.90 | $0 |
| Unknown Provider | — | — | $198.89 | $0 |
| Dr. Reginald Abraham, M D, M D | Specialist | Fountain Valley, CA | $198.89 | $0 |
| Dr. Charles Hobson, M.d, M.D | Critical Care Medicine | Gainesville, FL | $194.35 | $0 |
| Eric Rosero-Mora, M.d, M.D | Anesthesiology | Dallas, TX | $194.34 | $0 |
| Sudha Nayar, M.d, M.D | Nephrology | Charleroi, PA | $192.97 | $0 |
| Irfan Agha, M.d, M.D | Nephrology | Dallas, TX | $192.88 | $0 |
| Dr. Jeffrey Held, Md, MD | Internal Medicine | Attleboro, MA | $189.86 | $0 |
| Dr. Dana Campbell, M.d, M.D | Nephrology | Belleair, FL | $189.86 | $0 |
| Michael Robertson, Md, MD | Nephrology | Rockford, IL | $189.72 | $0 |
| Jennifer Johnson, Md, MD | Critical Care Medicine | Nashville, TN | $189.33 | $0 |
| Dennis Hong | Pulmonary Disease | Chicago, IL | $187.12 | $0 |
| Trudy Demko, Md, MD | Nephrology | Wyomissing, PA | $186.33 | $0 |
| Dr. Ramzi Vareldzis, Md, MD | Nephrology | Jackson, MS | $184.29 | $0 |
| Dr. Mihran Naljayan, M.d, M.D | Internal Medicine | New Orleans, LA | $184.29 | $0 |
| Dr. Michael Kalina, Do, DO | Surgery | Pennington, NJ | $179.20 | $0 |
| Jose Bernardo, M.d, M.D | Nephrology | Indiana, PA | $175.22 | $0 |
| Prashant Amin, M.d, M.D | Internal Medicine | Gainesville, GA | $169.14 | $0 |
| Dr. Ross Edmundson, M.d, M.D | Family Medicine | Orlando, FL | $165.10 | $0 |
| Dr. Tomas Jacome, Md, MD | Surgical Critical Care | Baton Rouge, LA | $165.03 | $0 |
| Dr. Ashish Agrawal, M.d, M.D | Critical Care Medicine | La Mesa, CA | $165.01 | $0 |
| Khalil Soomro, Md, MD | Internal Medicine | La Mesa, CA | $165.01 | $0 |
Top Products
- NephroCheck Test Kit $977,896
- Nephrocheck $486,082
Associated Products (8)
- NephroCheck Test Kit $998,041
- Nephrocheck $631,189
- Nephrocheck Test $451,048
- NEPHROCHECK TEST $372,069
- NEPHROCHECK $291,612
- NephroCheck Test $284,818
- NephroCheck Meter $106,095
- NEPHROCHECK Liquid Control Kit $32,780
Payment Categories
- Food & Beverage $44,223
- Consulting $320,183
- Travel & Lodging $41,027
- Research $1.8M
- Royalties $546,317
About Astute Medical, Inc.
Astute Medical, Inc. has made $3.2M in payments to 804 healthcare providers, recorded across 2,191 transactions in the CMS Open Payments database. In 2024, the company paid $104,587. The top product by payment volume is NephroCheck Test Kit ($977,896).
Payments were distributed across 48 medical specialties. The top specialty by payment amount is Critical Care Medicine ($97,299 to 93 doctors).
Payment categories include: Food & Beverage ($44,223), Consulting ($320,183), Research ($1.8M), Travel & Lodging ($41,027), Royalties ($546,317).
Astute Medical, Inc. is associated with 8 products in the CMS Open Payments database, including NephroCheck Test Kit, Nephrocheck, and Nephrocheck Test.